Glanzmann's thrombasthenia is an autosomal recessive disorder characterized by a lack of platelet aggregation due to the absence of platelet glycoprotein IIb and IIIa. Usually, the disease leads to mild hemorrhage but sometimes bleeding is severe enough to be life-threatening. We report the case of a 16-year-old girl, presenting with very severe type 1 Glanzmann's thrombasthenia, successfully treated with an HLA-identical sibling bone marrow transplant (BMT). We also update the clinical and laboratory data of her brother, who had received a BMT 16 years ago for the same disease. In the light of these two cases and two others published in the literature, we discuss the indications for BMT from HLAidentical sibling donors in Glanzmann's thrombasthenia. Alloimmunization against the missing platelet GPIIb/IIIa complex and severity of bleeding episodes may constitute sufficient criteria for allogeneic BMT after careful assessment of the risk-benefit of such a procedure, although this remains exceptional in this disease. Bone Marrow Transplantation (2000) 25, 327-330.
Glanzmann's thrombasthenia (GT) is an inherited autosomal recessive disorder, first described in 1918 as hemorrhage, prolonged bleeding time, normal platelet counts and morphology with defective clot retraction. 1 Subsequently, complete lack of platelet aggregation to all the agents tested was reported; the classification proposed in 1972 by Caen 2 distinguishes type 1 where clot retraction is absent and intracytoplasmic fibrinogen lacking, from type 2 where clot retraction is delayed and intracytoplasmic fibrinogen present but decreased. In 1974, the molecular defect was characterized as the absence of glycoproteins IIb (GPIIb) and IIIa (IIIa) bound together by Ca ++ bridging to form a stoechiometric complex. 3 This complex, also known as the integrin ␣ IIb ␤ 3 , brings the receptor from plasmatic fibrinogen unravelled after platelet activation and is required for platelet aggregation. Thus, the defect in platelet aggregation observed in GT can be directly related to a defect in fibrinogen binding which is either absent as in type 1, or considerably decreased as in type 2 GT. More recently, variant forms have been reported where the GPIIb/IIIa complex is present but qualitatively abnormal, leading to defective binding of fibrinogen. 4 The clinical course can be mild or characterized by repeated hemorrhages whose severity varies from patient to patient. These may be unpredictable in a given patient, sometimes leading to important morbidity or to life-threatening hemorrhages independent of the type of defect. Patients examined in our institution have required red cell transfusions in 84% of cases and mortality is relatively low only if careful supportive measures are available. 5 Therapy is based on supportive care including hemostatic procedures, antifibrinolytics agents, desmopressin for minor hemorrhages, and packed red cells or platelet concentrates for major hemorrhages. The main complication of platelet concentrate transfusions is the occurrence of alloimmunization against HLA antigens and the lacking GPIIb/IIIa complex. In this latter condition, patients become refractory to platelet transfusions, thus developing a poor prognosis.
Here, we report a 16-year-old patient, who presented with very severe bleeding and developed antiGPIIb/IIIa antibodies. She was successfully treated with a bone marrow transplant (BMT) (Figure 1 ). We also update the case of her brother who had been transplanted 16 years previously 6 ( Figure 1 ) and we review the two cases reported in the literature 7, 8 in an attempt to define the indications for BMT in GT.
Case reports

Case 1
A 16-year-old patient was diagnosed at the age of 2 years as having a type 1 GT because of a familial history of GT: a sister died from hemorrhagic complications due to GT, and one brother had received a BMT because of severe GT leading to life-threatening hemorrhages. 6 Type 1 GT was confirmed because platelet aggregation and clot retraction were repeatedly nil, and GPIIb/IIIa complex undetectable either by SDS-PAGE electrophoresis, immunoblotting or flow cytometry. 9 She had frequent epistaxis leading to severe anemia requiring continuous iron supplementation. Varicella was complicated by hemorrhages. Platelet transfusions were delayed until the age of 12 years when she received her first one. At the age of 15, she had her first menstrual period. This was very heavy, requiring tranexamic acid and hormonal therapy (Metergin-Lutenyl). Three weeks later, she developed appendicitis and peritonitis. Appendicectomy was performed under platelet cover. Unfortunately, after the third platelet transfusion, she developed clinical side-effects to platelet transfusions (fever, chills). An alloantibody against platelet membrane GPIIb/IIIa (which was absent before surgery) was detected, 8 days after surgery, by immunofluorescence 10 and confirmed by MAIPA 11 and immunoblotting. 12 There were no anti-HLA antibodies. This alloantibody was responsible for a state of complete refractoriness to platelet transfusions. Platelet recovery after transfusion, estimated by flow cytometry, 13 was normal during the first days after initiation of platelet transfusions. It was found to be decreased to 40% of the theoretical value on day 8 and zero on day 10. After surgery, moderate purpura and menorrhagia persisted. The alloantibody level decreased progressively and was undetectable 3 months later by both ELISA 14 and immunofluorescence. 10 Nevertheless, because of the risk of rebound if platelet transfusions were needed, and since she had a healthy HLA-identical brother, BMT was suggested.
On admission, she was in good health except for mild purpura and gum bleeding. The hemoglobin was 11.3 g/dl with a mean corpuscular volume of 78 3 , 4.7 × 10 9 normal white blood cell (WBC)/l and differential, 270 × 10 9 platelets/l; anti-GPIIb/IIIa and anti-HLA antibodies were negative. A central venous line was inserted under platelet cover. Eight days later, conditioning therapy was started and a transient reappearance of the anti-GPIIb/IIIa antibody was noted. The conditioning regimen consisted of 120 mg/kg of cyclosphosphamide administered over 2 consecutive days and 12.5 mg/kg of busulphan administered over 4 consecutive days, which led to the rapid disappearance of the circulating anti-GPIIb/IIIa antibody. Graftversus-host disease (GVHD) prophylaxis was with cyclosporin A and methotrexate. 15 Amoxicillin, pefloxacin, fluconazole, acyclovir and trimetoprine-sulfametoxazole were administered for prophylaxis. The donor was her HLAidentical brother, known to be heterozygous for the disease. She received 3.55 × 10 8 donor bone marrow nucleated cells/kg. Treatment-related toxicities were moderate (grade II mucosal toxicity) without hemorrhagic problems. CMV antigenemia (day 47) was successfully treated with ganciclovir. The bone marrow engrafted on day 19 post transplant (neutrophils Ͼ500 × 10 9 /l), and platelets reached more than 20 × 10 9 /l on day 37, when she became transfusion independent. She received a total of 25 platelet concentrates from irradiated leukodepleted apheresis platelets and achieved a platelet count above 50 × 10 9 /l on day 54. During this period, anti-GPIIb/IIIa antibodies remained undetectable and there was an excellent platelet recovery (after platelet transfusions) as assessed by the increase in the platelet count and the expression of a normal amount of platelet membrane GPIIb/IIIa. Skin and intestinal grade II acute GVHD developed on day 26 and was successfully treated with corticosteroids. Seven months after BMT, extensive chronic GVHD appeared (gastro-intestinal symptoms, extensive oral lichen, ulcerative oesophagitis and gastritis). It began to improve 11 months later allowing tapering of the immunosuppressive drugs. With a followup of more than 3 years after BMT, the patient is doing well and leads a normal life with normal blood counts. She experiences normal menses with hormone therapy. Detailed coagulation studies were performed 22 months after BMT: clot retraction was normal as was platelet aggregation after collagen, arachidonic acid, adrenaline or TRAP (thrombinrelated activating peptide). However, this was slightly decreased after ADP; platelet membrane GPIIb/IIIa complex was estimated by flow cytometry (which showed only one population of platelets) at about 50% of the normal values. These data are compatible with a GT heterozygous state.
Case 2
AB, brother of case 1, is the first patient with GT to receive a BMT carried out 16 years ago, because of the severity of the disease. 6 He was diagnosed as having type I thrombasthenia at the age of 2 years. At the age of 4, he had repeated life-threatening hemorrhages which required several transfusions. He developed antibodies anti-GPIIb/IIIa and became refractory to platelet transfusions. After a conditioning regimen with cyclophosphamide 50 mg/kg/day for 3 days and thoracoabdominal irradiation (6 Gy), he received 3.9 × 10 8 bone marrow nucleated cells/kg from his HLA-identical brother who was heterozygous for the disease. Graft failure with autologous reconstitution was documented 21 days after BMT. Recurrent intestinal bleeding occurred. On day 30, platelet aggregation confirmed the persistence of GT. Consequently, he was prepared for a second transplant with CCNU 300 mg/m 2 for 2 days, procarbazine 12.5 mg/kg for 3 days, horse anti-thymocyte globulin for 3 days and cyclophosphamide 50 mg/kg for 4 days followed by 6.3 × 10 8 nucleated cells/kg harvested from the same bone marrow donor. Engraftment was documented on day 30 following the second transplant and platelet independence was reached on day 34. The clinical course was complicated by CMV infection, acute and then chronic GVHD which resolved within 2 years after BMT. Since that time, no major clinical problems have occurred. There were no hemorrhages or infections and the patient received no further treatment. He is currently leading a normal life. Coagulation studies were performed 18 months, 12 years and 16 years after BMT, which confirmed correction of the GT. His clot retraction is now normal. Platelet aggregation in response to TRAP, arachidonic acid, collagen are normal and slightly decreased after ADP, suggesting a heterozygous disease state. Flow cytometry analysis confirmed the presence of about 50% of GPIIb/IIIa complex on all platelets with only one population of platelets. No platelet antibody is now present.
Discussion
To our knowledge, only two other cases of type 1 GT treated with BMT have been reported. 7, 8 In the case reported by Johnson et al 7 concerning a 4-year-old girl, the diagnosis of type 1 GT was made when she was 16 weeks old because of a history of spontaneous hemorrhage since birth. The patient suffered very frequent epistaxis and occasional rectal bleeding requiring more than 20 episodes in hospital before the age of 4 years. She had received only one transfusion. Because of the high morbidity of the disorder, a BMT from an HLA-identical sister was undertaken, who was an asymptomatic heterozygous carrier. It was assumed, although not documented, that the patient had not developed any anti-HLA or anti-GPIIb/IIIa antibody. Conditioning was with busulphan and cyclophosphamide. Engraftment was confirmed by platelet flow cytometry studies which showed the presence of GPIIb/IIIa at 50% of the normal values. Nineteen months after BMT, she was in good health with no hemorrhagic complications.
The case reported by McColl et al 8 concerns a 5-yearold boy. The diagnosis of type 1 GT was made in the neonatal period following the occurence of extensive nontraumatic bruising. The child suffered very frequent and severe epistaxes resistant to desmopressin or regular oral tranexamic acid. A bilateral limited septoplasty was performed on two occasions resulting in only transient improvement. The patient had received 185 units of red cell concentrates and 219 units of platelets when it was decided to perform a BMT because of the life-threatening bleeding episodes. The donor was an HLA-identical brother, heterozygous for the disease. Development of alloantibodies against HLA antigens and/or GPIIb/IIIa is not mentioned, although possible. Conditioning was with busulphan and cyclophosphamide. The patient showed no evidence of platBone Marrow Transplantation elet refractoriness despite large numbers of previous red cell and platelet transfusions nor did he develop any acute or chronic GVHD. He engrafted successfully with platelet counts of more than 50 × 10 9 /l on day 28. Engraftment was confirmed by platelet flow cytometry, showing the presence of membrane GPIIb/IIIa at 50% the normal values in agreement with a heterozygous disease state. Blood examination and clinical course, with no major hemorrhagic problems, were satisfactory 18 months post BMT.
Despite the favorable outcome and long-term cure of the four cases described, the indications for allogeneic BMT in this disease must be assessed, since clinically severe bleeding is rare. 5 Because of the risks involved in BMT, this should not be recommended early on as proposed by Johnson to avoid alloimmunization. 7 On the contrary, in patients with severe, persistent and life-threatening hemorrhages, and in those who develop anti-GPIIb/IIIa alloantibodies thus leading to a state of refractoriness to platelet transfusions and to a poor prognosis, we suggest that HLA-identical sibling BMT is a good option after careful evaluation of the risk-benefit of such a procedure.
